A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...
Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback